Another Chinese firm seeks permission for vaccine trial in Pakistan
ISLAMABAD: Covid-19 claimed 63 more lives while 2,260 new infections were reported during the last 24 hours in the country, said the National Command and Operation Centre (NCOC) on Saturday.
With these deaths and infections, the death toll has reached to 9,816 while the national tally of cases has moved up to 469,482.
A total of 1,531 patients recovered from the virus during the last 24 hours. However, 2,357 patients were stated to be in critical condition.
According to the NCOC, the total count of active cases now stands at 39,177.
A total of 36,909 tests were conducted across the country during the last 24 hours, while 6,523,842 samples were tested thus far.
Overall 420,489 people have recovered from the deadly disease in the country so far.
As per NCOC statistics, 209,429 cases have been reported in Sindh, 135,141 in Punjab, 56,875 in Khyber Pakhtunkhwa (KP), 18,061 in Balochistan, 39,981 in the federal capital Islamabad, 4,847 in Gilgit-Baltistan (GB) and 8,148 in Azad Jammu and Kashmir (AJK).
A total of 3,462 patients have died of coronavirus in Sindh, 3,858 in Punjab, 1,596 in KP, 404 in Islamabad, 181 in Balochistan, 101 in GB and 214 in AJK.
A total of 316 patients are on ventilators in different medical facilities across the country, whereas 2,840 patients are currently admitted to 615 hospitals.
Meanwhile, another Chinese pharmaceutical company has expressed interest in clinical trials of the Covid-19 vaccine in Pakistan.
Sources privy to the development said that another Chinese company named Zafai Longcom has contacted the Drug Regulatory Authority Pakistan (DRAP) and expressed its desire for clinical trials of Covid-19 vaccine in Pakistan.
The Chinese company has requested the DRAP for cooperation in this regard. A letter sent to the DRAP said that Zafai Longcom is a local pharmaceutical company in the Chinese province of Inoue, which has developed the corona vaccine in collaboration with the Chinese Academy of Sciences, and now wants clinical trials of possible vaccines in Pakistan.
The letter said that the clinical trials of the vaccine would be carried out in collaboration with a local pharma company. For the trials, the company wanted to transfer vaccines and test kits to Pakistan.
The company is currently testing its vaccine on 29,000 volunteers.
It may be mentioned that before this company, another company Sinopharma of China has also conducted its clinical trials in Pakistan.
Earlier, Federal Minister for Planning and Development Asad Umar had said that Pakistan is all set to participate in the phase-three trials of a Chinese developed coronavirus vaccine.
Special Assistant to the Prime Minister on National Health Services Dr Faisal Sultan said a day earlier that the government will prefer to import Covid-19 vaccine based on transparent scientific research data.
Talking to a private news channel, he said that six major international pharmaceutical companies are at the forefront of developing the coronavirus vaccine, but the company that will present scientific research data in a transparent manner will be contacted in this regard.
The special assistant on health said that providing low cost and quality vaccines to the people is a target, however, it is important to be completely safe. He made it clear that there will be no compromise on the quality of the vaccine.